Featured ArticlesJDD HighlightsJDD HiglightsJDD in the MediaThe Latest

JDD in the News: AI Perceptions, Platelet Count & Psoriasis

By March 17, 2022No Comments

By Allison Sit

Dermatology News, Dermatology Times and Practical Dermatology all wrote about the February JDD study, “Perceptions of Artificial Intelligence Integration into Dermatology Clinical Practice: A Cross-Sectional Survey Study.” Chapman Wei, MD, of Staten Island University Hospital Northwell Health, and researchers from the George Washington School of Medicine and Health Sciences found that dermatologists surveyed were generally positive toward embracing AI integration in clinical practice. More than 94% of respondents said they would at least use AI for certain scenarios, and more than 51% of respondents felt that AI will at least somewhat enhance dermatologists’ ability to screen skin lesions. Nearly 39% of respondents predict that AI would have no change on the need for dermatologists. The survey was distributed to subscribers of the ODAC Dermatology Aesthetic & Surgical Conference listserv.


Healio wrote two articles about studies from the February JDD. “Hematological parameters can be used to assess psoriasis severity ‘to some extent’” discusses the study, “Platelet Count, Mean Platelet Volume, and Red Cell Distribution Width as Markers for Psoriasis Severity,” by Safina Nageen and colleagues from hospitals and medical schools in Pakistan and New Jersey. Researchers evaluated the usage of complete blood count components (CBC) including platelet count, mean platelet volume (MPV), and red cell distribution width (RDW) as hematological markers for assessing psoriasis severity. Findings suggest that MPV, platelet count and RDW are useful in identifying psoriasis severity to some extent. The researchers noted that they foresee the use of these biomarkers as a complement to the PASI score in assessing psoriasis severity, and also as a means to determine the likelihood of developing comorbidities.


Healio also wrote about the February JDD study, “Self-administering bimekizumab via syringe, auto-injector sees similar success, safety.” The study, “Bimekizumab Self-Injection Devices: Two Multicenter, Randomized, Open-Label Studies on Self-Administration by Patients With Psoriasis,” was authored by Jerry Bagel, MD, UCB Pharma researchers and Michael Sebastian, MD, as substudies of the BE BRIGHT study. In the substudies, patients with moderate to severe plaque psoriasis received bimekizumab 320 mg (2×160 mg injections) every 4 or 8 weeks and were randomized 1:1 to the safety syringe or the auto-injector. Study authors found that patients with psoriasis were able to self-inject bimekizumab using both devices safely with an overall positive self-administration experience. Researchers noted that, when patients are provided with both injection options, patients can choose the device that best suits their preference on the amount of control they would prefer over the self-injection process.